Biotherapies, Inc. is dedicated to the development of better cancer treatment and diagnosis.
This statement is more than just a company slogan. Our technology makes us believe that we can develop better methods to deal with cancer. Recent developments have caused the medical community to consider that if we look at current cancer treatments logically we will note that each chemotherapy works only on a subset of patients, sometimes on a small subset. Consensus is emerging that we need to change that or at least find ways to determine what treatments will work for which patients. Recent development of biological treatments suggests the potential for a rational approach to cancer therapy that finds good targets for treatment, measures response from those targets and provides more benign therapy.
Biotherapies Incorporated has been working on the project that was outlined in an article in the February 11, 2003 issue of the Wall Street Journal entitled “Why Curing Your Cancer May Not Be the Best Idea”. This article described how many caner experts are starting to consider the idea of controlling cancer and treating it as a chronic disease. This is an idea that Biotherapies has been working on for the last eight years. The company intends to leverage its fifteen-year history with Mammastatin and breast cancer to develop therapies and diagnostic tools for first breast cancer and then other forms of human cancer including prostate, ovarian, skin and colon cancers.
Our approach has been to first look at the fundamental difference between normal cells and cancer cells. Normal cells grow in a controlled manner and cancer cell growth is uncontrolled. Cancer is then, a disease of abnormal growth control. We therefore began looking for things produced by normal cells that controlled cancer cell growth.
Mammastatin was the first unique protein that we identified as a growth regulator. The protein stops the growth of breast cancer cells. We have developed ways to use this protein to identify women at risk and we have also learned how to use this protein as a cancer therapy. We can identify women who are at risk of cancer because of lack of Mammastatin, target the specific abnormality of Mammastatin deficiency, and treat that deficiency with Mammastatin therapy. Doing this allows us to stop breast cancer.
We plan to take a similar approach to all human cancers.